Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 4/20 | 0.41 |
| ▸ | HPGD | P15428 | 8/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | USP7 | Q93009 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | SLC6A7 | Q99884 | 1/20 | 0.40 |
| ▸ | NAMPT | P43490 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2400885 | 0.89 | ABL1 (0.46) | SMN1; SMN2HTTRAB9AHPGDALDH1A1 | |
| SCHEMBL6410752 | 0.85 | USP7 (0.39) | SMN1; SMN2HTTRAB9AHPGDALDH1A1 | |
| SCHEMBL2581596 | 0.84 | HPGD (0.39) | SMN1; SMN2RAB9AHPGDALDH1A1NPC1 | |
| SCHEMBL2403261 | 0.83 | HTR1A (0.45) | ALDH1A1 | |
| SCHEMBL2401978 | 0.83 | RAB9A (0.45) | RAB9AHPGDALDH1A1NPC1MAPT | |
| SCHEMBL2575305 | 0.81 | SMN1; SMN2 (0.45) | SMN1; SMN2HTTHPGDALDH1A1TSHR | |
| SCHEMBL2402651 | 0.81 | HPGD (0.43) | SMN1; SMN2HTTRAB9AHPGDALDH1A1 | |
| SCHEMBL6785148 | 0.80 | HPGD (0.40) | SMN1; SMN2HTTRAB9AHPGDALDH1A1 | |
| SCHEMBL2401537 | 0.80 | AVPR1A (0.43) | SMN1; SMN2HTTHPGDALDH1A1PKM | |
| SCHEMBL2400758 | 0.80 | SLC6A7 (0.44) | SMN1; SMN2HTTALDH1A1TSHRMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8048890-B2 | Analgesics; neuropathic pain; headaches; muscle relaxants; incontence; tinnitus; diarrhea; antiarrhythmia agents; antiischemic agents; antiinflammatory agents; antiulcer agents; antidepressants; antiepileptic agents | GRUENENTHAL GMBH (DE) | 2011-11-01 | — | — | US | claimed |
| US-8048890-B2 | Analgesics; neuropathic pain; headaches; muscle relaxants; incontence; tinnitus; diarrhea; antiarrhythmia agents; antiischemic agents; antiinflammatory agents; antiulcer agents; antidepressants; antiepileptic agents | GRUENENTHAL GMBH (DE) | 2011-11-01 | — | — | US | disclosed |
| US-20110224172-A1 | Substituted 1-Oxa-2,8-Diaza-Spiro [4,5] Dec-2-Ene Derivatives and Related Treatment Methods | GRUENENTHAL GMBH (DE) | 2011-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110224172-A1 | Substituted 1-Oxa-2,8-Diaza-Spiro [4,5] Dec-2-Ene Derivatives and Related Treatment Methods | SULT1E1, DECR1, CYP8B1 | SMN1; SMN2 1407/4885HTT 2094/4885RAB9A 2221/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.